Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease

Abstract Background Oncostatin M (OSM) has been implicated in the pathogenesis of inflammatory bowel disease (IBD) and as a marker for nonresponsiveness to anti-tumor necrosis factor (TNF) therapy. We further unraveled the potential of OSM and related receptors as markers of diagnosis, prognosis, and therapy response in IBD. Methods We collected inflamed mucosal biopsies and serum from patients with Crohn disease (CD) and with ulcerative colitis: (1) newly diagnosed patients who were treatment-naïve, (2) patients initiating anti-TNF or (3) vedolizumab therapy, (4) postoperative patients with CD, and (5) multiple-affected families with IBD including unaffected first-degree relatives (FDRs). We measured the gene expression of mucosal OSM and its receptors OSMR/LIFR and co-receptor IL6ST, and the protein expression of serum OSM. Statistical significance was defined as P < 0.05. Results Newly diagnosed patients showed significantly increased mucosal OSM/OSMR compared with control patients, with the highest enrichment for OSM (fold change [FC] >17.9). Likewise, ileal OSM/OSMR were significantly upregulated in postoperative recurrent CD. Serum OSM was increased in newly diagnosed patients and postoperative patients with recurrent CD (FC ≥ 2.6). In families with IBD, higher serum levels were observed in FDRs than in control families (FC = 2.2). Furthermore, elevated colonic OSM/OSMR (but not serum OSM) were associated with the early need for biologic therapy (FC ≥ 1.9), and higher OSM was also predictive of primary nonresponse to both anti-TNF and vedolizumab therapy (FC ≥ 2.4). Immunohistochemistry highlighted mucosal OSM expression in macrophages. Conclusions We found that OSM is a diagnostic biomarker in the tissue and serum not only of newly diagnosed patients with IBD and postoperative patients with recurrent CD but also of their FDRs. Higher colonic OSM levels are furthermore associated with poor prognosis and with primary nonresponse to biologic therapies. Therefore, OSM could guide clinical decision-making.

[1]  L. Baglietto,et al.  Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab , 2020, Alimentary pharmacology & therapeutics.

[2]  J. Murray,et al.  Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 y Before Diagnosis. , 2020, Gastroenterology.

[3]  T. Ahmad,et al.  DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn’s disease: A pilot serum proteomic analysis of the PANTS cohort , 2020 .

[4]  M. Parkes,et al.  Personalised medicine in Crohn's disease. , 2020, The lancet. Gastroenterology & hepatology.

[5]  L. Denson,et al.  Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab , 2019, Crohn's & colitis 360.

[6]  P. Rutgeerts,et al.  Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease. , 2019, Journal of Crohn's & colitis.

[7]  N. West,et al.  Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines , 2019, Front. Immunol..

[8]  A. Paterson,et al.  Sa1816 – Elevated Fecal Calprotectin in Healthy First Degree Relatives of Patients with Crohn's Disease is Associated with Future Diagnosis of Crohn's Disease , 2019, Gastroenterology.

[9]  Shanrong Zhao,et al.  Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers , 2019, Journal of Crohn's & colitis.

[10]  S. Vermeire,et al.  Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease , 2019, EBioMedicine.

[11]  S. Shen-Orr,et al.  Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response , 2019, Nature Communications.

[12]  S. Vermeire,et al.  New biologics and small molecules in inflammatory bowel disease: an update , 2019, Therapeutic advances in gastroenterology.

[13]  Judy H. Cho,et al.  Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy , 2019, Cell.

[14]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.

[15]  S. Vermeire,et al.  TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn’s disease patients? , 2018, Gut.

[16]  A. Hegazy,et al.  The oncostatin M‐stromal cell axis in health and disease , 2018, Scandinavian journal of immunology.

[17]  S. Shen-Orr,et al.  Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD , 2018, Gut.

[18]  D. Repsilber,et al.  Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles , 2017, PloS one.

[19]  G. Müller-Newen,et al.  Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease , 2017, Zeitschrift für Gastroenterologie.

[20]  L. Peyrin-Biroulet,et al.  Ulcerative colitis , 2017, The Lancet.

[21]  L. Peyrin-Biroulet,et al.  Crohn's disease , 2017, The Lancet.

[22]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[23]  R. Owens,et al.  Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease , 2017, Nature Medicine.

[24]  Masa Umicevic Mirkov,et al.  Genetics of inflammatory bowel disease: beyond NOD2. , 2017, The lancet. Gastroenterology & hepatology.

[25]  G. Fiorino,et al.  Diagnostic Delay in Crohn’s Disease: Time for Red Flags , 2016, Digestive Diseases and Sciences.

[26]  J. Mclaughlin,et al.  What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance , 2016, Journal of Crohn's & colitis.

[27]  C. Appleyard,et al.  Colonic macrophage polarization in homeostasis, inflammation, and cancer. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[28]  A. Paterson,et al.  IBD Genetic Risk Profile in Healthy First-Degree Relatives of Crohn's Disease Patients. , 2016, Journal of Crohn's & colitis.

[29]  H. Hermanns.  Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. , 2015, Cytokine & growth factor reviews.

[30]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[31]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[32]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[33]  P. Rutgeerts,et al.  Sa1198 Agreement Among Experts in the Endoscopic Evaluation of Postoperative Recurrence in Crohn's Disease Using the Rutgeerts Score , 2014 .

[34]  S. Plevy,et al.  The Role of Macrophages and Dendritic Cells in the Initiation of Inflammation in IBD , 2014, Inflammatory bowel diseases.

[35]  C. Richards.  The Enigmatic Cytokine Oncostatin M and Roles in Disease , 2013, ISRN inflammation.

[36]  Kristel Van Steen,et al.  Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease‡ , 2010, Inflammatory bowel diseases.

[37]  G Van Assche,et al.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.

[38]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[39]  D. Friend,et al.  Dual Oncostatin M (OSM) Receptors , 1996, The Journal of Biological Chemistry.

[40]  Comeau,et al.  The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. , 1992, Science.

[41]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[42]  P. Rutgeerts,et al.  Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. , 1984, Gut.

[43]  A. Zorluoğlu,et al.  Oncostatin-M as a novel biomarker in colon cancer patients and its association with clinicopathologic variables. , 2014, European review for medical and pharmacological sciences.